Pathania J, Pathania V. Real-world effectiveness and safety of teduglutide in patients with short bowel syndrome. World J Gastrointest Pharmacol Ther 2026; 17(1): 117071 [DOI: 10.4292/wjgpt.v17.i1.117071]
Corresponding Author of This Article
Jyoti Pathania, Department of Anesthesia, Rohilkhand Medical College, Pilbhit bypass road, Bareilly 243006, Uttar Pradesh, India. pathaniajyoti7@gmail.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Mar 5, 2026 (publication date) through Feb 11, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pharmacology and Therapeutics
ISSN
2150-5349
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Pathania J, Pathania V. Real-world effectiveness and safety of teduglutide in patients with short bowel syndrome. World J Gastrointest Pharmacol Ther 2026; 17(1): 117071 [DOI: 10.4292/wjgpt.v17.i1.117071]
World J Gastrointest Pharmacol Ther. Mar 5, 2026; 17(1): 117071 Published online Mar 5, 2026. doi: 10.4292/wjgpt.v17.i1.117071
Real-world effectiveness and safety of teduglutide in patients with short bowel syndrome
Jyoti Pathania, Vanya Pathania
Jyoti Pathania, Department of Anesthesia, Rohilkhand Medical College, Bareilly 243006, Uttar Pradesh, India
Vanya Pathania, Department of Gynaecology and Obstretics, Maharishi Markandeshwar Medical College and Hospital, Solan 173229, Himāchal Pradesh, India
Author contributions: Pathania J wrote the initial manuscript; Pathania V collected all the literature; Pathania J wrote and edited the final draft. All authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jyoti Pathania, Department of Anesthesia, Rohilkhand Medical College, Pilbhit bypass road, Bareilly 243006, Uttar Pradesh, India. pathaniajyoti7@gmail.com
Received: November 28, 2025 Revised: December 17, 2025 Accepted: January 26, 2026 Published online: March 5, 2026 Processing time: 75 Days and 22.6 Hours
Core Tip
Core Tip: Teduglutide (rDNA) is a Food and Drug Administration sanctioned medication for individuals with short bowel syndrome. The majority of short bowel syndrome patients receive parenteral support, and this medication enhances their chances of achieving parenteral independence to different extents. Daily subcutaneous injections are routinely prescribed, along with regular gastrointestinal colonoscopies/endoscopies to observe the enterocyte dysplasia present in certain individuals. The expensive nature of the treatment significantly discourages its regular use, leading the prescribing physician to adjust its dosage. Nonetheless, only a limited number of treatment-related side effects are seen, making it the sole pharmacological choice for these patients.
